Healthcare Analyst Fadia, along with Specialty Pharma Expert Kevin O’Keeffe, discuss factors to consider in estimating the number of patients that will eventually get AVDL‘s Lumryz based on enrollment in the RYZUP patient support services hub on an Analyst/Industry conference call to be held on October 3 at 11 am.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVDL:
- Needham healthcare analyst to hold an analyst/industry conference call
- Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- Avadel Pharmaceuticals price target raised to $18 from $13 at Piper Sandler
- Avadel Pharmaceuticals reports Q2 EPS (83c), consensus (38c)
- Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results